Soft tissue sarcomas, a look into the future: different treatments for different subtypes (Q38232373)

31 August 2017

Soft tissue sarcomas, a look into the future: different treatments for different subtypes (English)

1 reference

31 August 2017

Peter Reichardt

1

1 reference

PubMed ID

25048045

31 August 2017

language of work or name

English

0 references

publication date

1 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

8 Suppl

1 reference

31 August 2017

s19-27

1 reference

Current questions in soft tissue sarcoma: further steps with Yondelis®.

31 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

The evolution of systemic therapy in sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Histology-driven chemotherapy of soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

New agents for the treatment of lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Malignant fatty tumors: classification, clinical course, imaging appearance and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Pazopanib: in advanced soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Malignant fibrous histiocytoma: changing perceptions and management challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Alveolar soft-part sarcoma: a review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Cediranib for metastatic alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma G

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.116

21 January 2018

Identifiers

DOI

10.2217/FON.14.116

1 reference

31 August 2017

1 reference

PubMed ID

25048045